What is the share price of Nectar Lifesciences Ltd (NECLIFE) today?
The share price of NECLIFE as on 7th March 2025 is ₹29.23. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nectar Lifesciences Ltd (NECLIFE) share?
The past returns of Nectar Lifesciences Ltd (NECLIFE) share are- Past 1 week: 5.89%
- Past 1 month: -23.54%
- Past 3 months: -12.01%
- Past 6 months: -43.23%
- Past 1 year: -18.24%
- Past 3 years: 15.08%
- Past 5 years: 183.79%
What are the peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE)?
The peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE) include:What is the market cap of Nectar Lifesciences Ltd (NECLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nectar Lifesciences Ltd (NECLIFE) is ₹655.51 Cr as of 7th March 2025.What is the 52 week high and low of Nectar Lifesciences Ltd (NECLIFE) share?
The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is ₹56.50 and the 52-week low is ₹24.77.What is the PE and PB ratio of Nectar Lifesciences Ltd (NECLIFE) stock?
The P/E (price-to-earnings) ratio of Nectar Lifesciences Ltd (NECLIFE) is 131.37. The P/B (price-to-book) ratio is 0.61.Which sector does Nectar Lifesciences Ltd (NECLIFE) belong to?
Nectar Lifesciences Ltd (NECLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nectar Lifesciences Ltd (NECLIFE) shares?
You can directly buy Nectar Lifesciences Ltd (NECLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nectar Lifesciences Ltd
NECLIFENectar Lifesciences Ltd
NECLIFE


Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
38.56 | 0.61 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
47.25 | 6.02 | 0.55% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
Peers
Compare with peersGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,681.46 | 1,666.37 | 1,882.29 | 2,788.91 | 2,370.70 | 1,547.08 | 1,680.15 | 1,566.85 | 1,698.66 | 1,687.04 | ||||||||||
Raw Materials | 1,198.70 | 1,145.85 | 1,417.32 | 2,268.13 | 1,862.83 | 1,052.82 | 1,207.32 | 1,200.84 | 1,242.45 | 1,507.40 | ||||||||||
Power & Fuel Cost | 87.89 | 75.44 | 91.85 | 103.47 | 92.72 | 84.63 | 101.41 | 127.39 | 129.52 | |||||||||||
Employee Cost | 78.38 | 75.54 | 74.65 | 76.54 | 78.19 | 70.59 | 71.91 | 75.14 | 81.71 | |||||||||||
Selling & Administrative Expenses | 56.54 | 59.98 | 52.23 | 67.99 | 67.01 | 72.04 | 66.86 | 62.64 | 61.39 | |||||||||||
Operating & Other expenses | 15.44 | 62.48 | 4.06 | 2.56 | 45.89 | 179.49 | 62.79 | 4.66 | 17.46 | |||||||||||
EBITDA | 244.51 | 247.08 | 242.18 | 270.22 | 224.06 | 87.51 | 169.86 | 96.18 | 166.13 | 179.64 | ||||||||||
Depreciation/Amortization | 57.39 | 62.25 | 64.31 | 63.26 | 60.77 | 60.25 | 56.97 | 59.12 | 60.72 | 61.32 | ||||||||||
PBIT | 187.12 | 184.83 | 177.87 | 206.96 | 163.29 | 27.26 | 112.89 | 37.06 | 105.41 | 118.32 | ||||||||||
Interest & Other Items | 123.31 | 117.41 | 115.20 | 148.14 | 125.83 | 112.04 | 78.81 | 79.49 | 87.14 | 81.07 | ||||||||||
PBT | 63.81 | 67.42 | 62.67 | 58.82 | 37.46 | -84.78 | 34.08 | -42.43 | 18.27 | 37.25 | ||||||||||
Taxes & Other Items | 9.59 | 12.08 | 10.41 | 11.22 | 5.68 | -11.50 | 9.03 | -18.24 | 13.28 | 20.25 | ||||||||||
Net Income | 54.22 | 55.34 | 52.26 | 47.60 | 31.78 | -73.28 | 25.05 | -24.19 | 4.99 | 17.00 | ||||||||||
EPS | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | 0.76 | ||||||||||
DPS | 0.10 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.04 | 0.02 | 0.02 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Nectar Lifesciences Ltd | 131.37 | 0.61 | — |
Sun Pharmaceutical Industries Ltd | 40.32 | 5.75 | 0.84% |
Cipla Ltd | 28.58 | 4.39 | 0.89% |
Torrent Pharmaceuticals Ltd | 62.81 | 15.17 | 0.91% |
Price Comparison
Compare NECLIFE with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 11.27%
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 8.40%
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 1.84%
Shareholding Pattern
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 11, 2020
Dividend/Share
₹0.05
Ex DateEx Date
Sep 11, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 19, 2018
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2018
Cash Dividend
Ex DateEx DateSep 20, 2017
Dividend/Share
₹0.05
Ex DateEx Date
Sep 20, 2017
Cash Dividend
Ex DateEx DateSep 22, 2016
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2016
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales454.33452.16 0 OPM %9.849.33 - PBDT28.1617.83 58 PBT12.552.46 410 NP7.841.57 399 Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales427.88397.96 8 OPM %10.136.75 - PBDT24.2116.95 43 PBT8.671.64 429 NP5.601.02 449 Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
Net profit of Nectar Lifescience rose 63.19% to Rs 2.97 crore in the quarter ended June 2024 as against Rs 1.82 crore during the previous quarter ended June 2023. Sales declined 8.95% to Rs 358.85 crore in the quarter ended June 2024 as against Rs 394.12 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales358.85394.12 -9 OPM %11.099.02 - PBDT20.3818.39 11 PBT4.923.06 61 NP2.971.82 63 Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

Nectar Lifesciences stock ends 4.5% down after board nods sale of various assets to repay bank loans

Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -9.44%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.27% to 0.45%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -36.31%, vs industry avg of 15.27%